VCAR300 / VITRUVIAE - LARVOL DELTA

Anti-tumor activity of Man 9 x PS targeting immunotherapies in diffuse intrinsic pontine glioma (DIPG) and pancreatic cancers. (ASCO 2026) - "Man9 x PS dual targeting is a promising strategy for treating solid tumors. VTRU200 and VCAR300 are potential therapeutic candidates with potent anti-tumor activity across multiple tumor types and impressive safety. Following a successful pre-IND interaction with the FDA, first-in-human studies are planned to initiate in 2027."

First-in-human • IO biomarker • Acute Myelogenous Leukemia • Brain Cancer • Breast Cancer • Diffuse Intrinsic Pontine Glioma • Glioma • Hematological Malignancies • Leukemia • Oncology • Pancreatic Cancer • Solid Tumor • CD133

A Man9xPS CAR T cell immunotherapy demonstrates robust preclinical safety and efficacy in an orthotopic pancreatic cancer model (AACR 2025) - "Man9xPS CAR T cell therapy exhibits strong preclinical efficacy and specificity in targeting tumors characterized by aberrant high-mannose glycans and PS lipids. These findings support the potential of Man9xPS CAR T cells as a novel immunotherapy forpancreatic cancer, a challenging disease with known antigen escape mechanisms and genetic heterogeneity. Ongoing studies will further elucidate their therapeutic potential and safety, paving the way for clinical translation.This abstract was reviewed and edited with the assistance of artificial intelligence (AI) tools to enhance clarity, grammar, and overall readability."

CAR T-Cell Therapy • IO biomarker • Late-breaking abstract • Preclinical • Acute Myelogenous Leukemia • Breast Cancer • Hematological Malignancies • Leukemia • Liver Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor